Reduction of stress--a new therapeutic goal in the treatment of inflammatory bowel disease?
Eysselein
V E
VE
Harbor-UCLA Medical Center, Torrance, California, USA.
D000818:Animals; D018791:CD4 Lymphocyte Count; D004139:Dinitrofluorobenzene / Q000031:analogs & derivatives / Q000627:therapeutic use; D004195:Disease Models, Animal; D006241:Haptens / Q000627:therapeutic use; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000276:immunology / Q000523:psychology* / Q000628:therapy; D051379:Mice; D013315:Stress, Psychological
D006241:Haptens; C045305:2,4-dinitrofluorobenzene sulfonic acid; D004139:Dinitrofluorobenzene